secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2026-08-13T11:15:56+00:00
Accession:  0001919246-26-000112
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 4.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos restates Q1 2026 financials; Q2 net loss $23.4M, Zelsuvmi revenue up 45% QoQ
--------------------------------------------------------------------------------

- Restating Q1 2026 (March 31) financials; prior statements no longer reliable per Item 4.02.
- Q2 2026 net loss $(23.4)M vs $(25.1)M Q1; adjusted EBITDA $(5.7)M vs $(8.0)M.
- Zelsuvmi net revenue $15.4M, up 45% QoQ; 11,925 units dispensed by 4,571 prescribers.
- Cash $24.2M at June 30; $50M Horizon facility drawn $30M, $10M more available at lender discretion.
- COGS $3.6M includes $0.9M API write-off; SG&A $27.7M includes $5.3M non-recurring milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000112/0001919246-26-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000112/pths-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001919246-26-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer